SomaGen is showing strong performance. This is interpreted as highlighting its collaborative relationship with Moderna, a U.S. company known for its COVID-19 vaccine, which announced plans to release mRNA vaccines for cancer and cardiovascular diseases by 2030.
As of 10:06 AM on the 10th, SomaGen is trading at 7,800 KRW, up 3.17% compared to the previous day.
According to foreign media on the 7th (local time), Moderna announced it will release vaccines by 2030 that prevent and treat cancer, cardiovascular diseases, autoimmune diseases, and more. Experts expect these groundbreaking new vaccines for various diseases, including cancer, to save millions of lives.
This aligns with the direction of the U.S. cancer conquest project. On the 3rd (local time), the U.S. Department of Health and Human Services (HHS) unveiled a draft of the detailed plan for the Biden administration’s cancer conquest project, “Cancer Moonshot.” Cancer Moonshot is a policy goal announced by the U.S. government to reduce the cancer mortality rate among Americans by 50% within the next 25 years.
Meanwhile, SomaGen is growing alongside Moderna. A SomaGen official stated, “Quarterly sales to Moderna have increased about fourfold,” adding, “As Moderna accelerates cancer vaccine development, requests for genomic sequencing (CES) have surged.”
They continued, “Moderna used to distribute genomic analysis requests in small portions here and there, but from the second half of this year, they have concentrated these requests to a few companies including SomaGen,” explaining, “SomaGen’s genomic analysis is cost-effective, accurate, and meets delivery deadlines well.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
